摘要
目的:评价2种方案治疗耐多药肺结核的疗效及经济性。方法:将80例耐多药肺结核患者随机分为2组,各40例。2组除均给予一定量的利福喷丁、吡嗪酰胺、对氨基水杨酸、丙硫异烟胺、乙胺丁醇外,治疗组给予司帕沙星,对照组给予氧氟沙星,疗程12个月。观察2组疗效及不良反应,并采用成本-效果分析法进行评价。结果:治疗组与对照组成本分别为10143.25、7841.65元,治疗12个月后痰菌转阴率分别为90.0%、70.0%(P<0.05),成本-效果比分别为11270.28、11202.36,2组均未见明显不良反应。2a后随访,治疗组未见复发病例,对照组复发率20.0%。结论:从药物经济学的角度来看,司帕沙星治疗耐多药肺结核各项临床指标、总有效率及远期复发率均比氧氟沙星优越。
OBJECTIVE： To evaluate the cost effectiveness of two therapeutic schemes for treatment of multi- drug resistant pulmonary tuberculosis. METHODS： 80 multi- drug resistant pulmonary tuberculosis patients were randomly assigned to receive Sparfloxacine （trial group） or Ofloxacin （control group） plus anti- TB drugs （Rifapentine, Pyrazinamide, Sodium Aminosalicylate ~ Protionamide and Ethambatol） for 12 months. The curative effects and adverse drug reactions were monitored and the cost- effectiveness analyses were conducted. RESULTS： The costs in two groups （Sparfloxacin vs. Ofloxacin） were 10 143.25 and 7 841.65yuan, respectively; the negative- conversion rates of sputum bacteria after treatment for 12 months were 90.0% and 70.0%, respectively（P〈0.05）; the cost- effectiveness ratios were 11 270.28 and 11 202.36, respectively. No severe adverse reactions were noted in two groups. The recurrence rate in treatment group （0%） was lower than that in control group （20.0%） in the follow- up of two years. CONCLUSION： Sparfloxacin showed remarkable efficacy for multidrug resistant pulmonary tuberculosis for its advantages of low dosage, short course of treatment and low recurrence rate.
出处
《中国药房》
CAS
CSCD
北大核心
2009年第8期563-565,共3页
China Pharmacy
关键词
耐多药肺结核
司帕沙星
氧氟沙星
成本-效果分析
Multi- drug resistant pulmonary tuberculosis
Sparfloxacin
Ofloxacin
Cost-effectiveness analysis
